Talaris Therapeutics Inc Stock

$26.74

6.53%

Nasdaq, Sep 05, 10:00 pm CET

ISIN

US87410C1045

Symbol

TRML

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Talaris Therapeutics Inc Stock price

$26.74

-48.77 64.59% 5Y

Nasdaq, Closing price Fri, Sep 05 2025

+1.64 6.53%

ISIN

US87410C1045

Symbol

TRML

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$687.0m

Enterprise Value

$447.8m

Net debt

positive

Cash

$239.2m

Shares outstanding

25.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 89.8

EV/Sales

- | 58.5

EV/FCF

negative

P/B

2.7

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | -50.9%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$0.0 | $7.7m

EBITDA

$-102.0m | -

EBIT

$-102.0m | $-104.5m

Net Income

$-88.3m | $-90.6m

Free Cash Flow

$-86.2m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-127.8% | -

EBIT

-130.0% | -16.4%

Net Income

-150.8% | -23.8%

Free Cash Flow

-197.1%

Financial Health

Equity Ratio

97.1%

Return on Equity

-24.4%

ROCE

-39.4%

ROIC

Debt/Equity

0.0

EPS

$-3.4

FCF per Share

$-3.4

Short interest

10.9%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Get Started for Free Today

Talaris Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Talaris Therapeutics Inc forecast:

16x Buy

94%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Talaris Therapeutics Inc forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Talaris Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	23 23	72% 72% -
- Research and Development Expense	80 80	90% 90% -
EBITDA	-102 -102	128% 128% -
- Depreciation and Amortization	0.04 0.04	110% 110% -
EBIT (Operating Income) EBIT	-102 -102	130% 130% -
Net Profit	-88 -88	151% 151% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Talaris Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

8 days ago

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary pharmacodynamic biomarkers of IL-6 pathway activity including lipoprotein(a), fibrinogen, and serum amyloid A – NEW YORK, Aug. 31, 2025 (GLOBE NEWSW...

Neutral

GlobeNewsWire

●

26 days ago

Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – — Additional data from the ongoing Phase 2 TRANQUILITY trial to be presented at the European Society of Cardiology Congress in August 2025 – – On track to initiate Phase 2 proof...

Positive

Seeking Alpha

●

4 months ago

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing pacibekitug to a phase 3 cardiovascular outcomes trial for ASCVD, pending an FDA meeting in late 2025. The 7 major Atherosclerotic Cardiovascular Disease markets are expected to reach $30.6 billion by ...

More Talaris Therapeutics Inc News

Company Profile

Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad in 2002 and is headquartered in Louisville, KY.

Head office	United States
CEO	Sandeep Kulkarni
Employees	74
Founded	2021
Website	www.tourmalinebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now